Journal List > J Rheum Dis > v.21(5) > 1064140

Kim, Lee, Im, Yeo, Lee, and Byun: A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis

Abstract

Infliximab, which is indicated for refractory rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Crohn's disease, has cutaneous adverse events including skin rash, urticaria, pruritus, and lupus-like eruption. Psoriasis induced by infliximab is very rare. In Korea, it is infrequently reported in Crohn's disease or RA and never reported in AS. We encountered a case of psoriasis induced by infliximab treatment for AS, and report here on this case along with a review of the relevant literature.

REFERENCES

1. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7:R666–76.
2. Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol. 2013; 12:939–43.
3. Kim JY, Choi M, Cho KH. A case of pustular psoriasis developed during infliximab treatment for crohn's disease. Korean J Dermatol. 2012; 50:810–3.
4. Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, et al. A case of psoriasis induced by infliximab treatment for Crohn's disease. Korean J Gastroenterol. 2010; 56:324–8.
crossref
5. Park BC, Lim HJ, Kim BS, Lee WJ, Kim do W, Lee SJ. Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease. Ann Dermatol. 2009; 21:60–2.
crossref
6. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. Korean J Dermatol. 2008; 46:721–3.
7. Kim SY, Kim GM, Kim SY. Case of recurrent generalized pustular psoriasis treated with a combination of infliximab with methotrexate and retinoid. Korean J Dermatol. 2006; 44:67–70.
8. Oh JM, Koh EM, Kim H, Lee J, Ahn JK, Cha HS, et al. Exacerbation of psoriatic skin lesion followed by tnfalpha antagonist treatment. J Korean Rheum Assoc. 2010; 17:200–4.
9. Park JJ, Lee SC. A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis. Ann Dermatol. 2010; 22:212–5.
10. Hahn HJ, Jung JW, Park HJ, Lee YW, Choe YB, Ahn KJ. A case of psoriasiform dermatitis following adalimumab injection for treatment of ankylosing spondylitis. Korean J Dermatol. 2013; 51:743–5.
11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496–509.
crossref
12. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58:501–8.
crossref
13. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012; 30:700–6.
14. Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140:1490–5.
crossref
15. Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005; 44:172–5.

Figure 1.
(A) Erythematous scaly plaques on extensor surfaces of lower extremities (B) pustules with reddened skin of palm.
jrd-21-274f1.tif
Figure 2.
Anteroposterior radiograph of the pelvis showing periarticular erosions and sclerosis of both sacroiliac joints.
jrd-21-274f2.tif
Figure 3.
Microscopic finding of the skin lesion. Hyperkeratosis, dermal papillar elongation, perivascular lymphocytic infiltration were seen (H&E stain, ×100).
jrd-21-274f3.tif
TOOLS
Similar articles